ChemicalBook > CAS DataBase List > Eculizumab

Eculizumab

Product Name
Eculizumab
CAS No.
219685-50-4
Chemical Name
Eculizumab
Synonyms
H5G1.1;Alexion;Soliris;Eculizumab;ECULIZUMABUM;Unii-A3ulp0F556;H5G1.1Vhc H5G1.1vlc;Eculizumab USP/EP/BP;Eculizumab, stock solution;Eculizumab (anti-Complement C5)
CBNumber
CB02491712
Formula Weight
0
MOL File
Mol file
More
Less

Eculizumab Property

storage temp. 
Store at -20°C
form 
Liquid
color 
Colorless to light yellow
CAS DataBase Reference
219685-50-4
More
Less

Safety

Hazardous Substances Data
219685-50-4(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
API0007496
Product name
ECULIZUMAB
Purity
95.00%
Packaging
5MG
Price
$498.98
Updated
2021/12/16
Biosynth Carbosynth
Product number
BE165588
Product name
Eculizumab
Packaging
1mg
Price
$500
Updated
2021/12/16
Biosynth Carbosynth
Product number
BE165588
Product name
Eculizumab
Packaging
2mg
Price
$700
Updated
2021/12/16
Biosynth Carbosynth
Product number
BE165588
Product name
Eculizumab
Packaging
5mg
Price
$1000
Updated
2021/12/16
DC Chemicals
Product number
013343
Product name
Eculizumab
Packaging
002
Price
$1200
Updated
2021/12/16
More
Less

Eculizumab Chemical Properties,Usage,Production

Description

Eculizumab, a fully humanized anti-C5 monoclonal antibody, was introduced for treating patients with PNH to reduce hemolysis. It is the first therapy to be approved for this rare and life-threatening form of hemolytic anemia. PNH is a clonal hematopoietic stem-cell disorder that is characterized by the production of abnormal red blood cells (RBCs) with a deficiency of surface proteins that protect the cells against attack by the body’s complement system. Complement-mediated destruction of the susceptible RBCs results in intravascular hemolysis, the primary clinical manifestation in all PNH patients. Previously, patients with PNH have mainly been managed supportively, with red cell transfusions as required, and treatments such as folate and iron supplementation, anticoagulation for thrombotic disease, and the occasional use of steroids during hemolytic crises. Allogenic stem cell transplantation is currently the only curative option for PNH; however, it is associated with significant morbidity and mortality. Eculizumab therapy is aimed at preventing red cell lysis through blockade of complement activation process and the production of the membrane attack complex. Eculizumab specifically binds to the human complement protein C5 with high affinity (IC50 = 2 nM) and inhibits its cleavage to C5a and C5b, which is a key step in the pathway leading to the membrane attack complex C5b-C9.
Eculizumab has been granted orphan drug status from both the FDA and European regulatory agencies.The most serious adverse reaction associated with eculizumab therapy is meningococcal infections. Eculizumab is contraindicated in patients who are not vaccinated against Neisseria meningitidis or who have N. meningitidis infections. The most common adverse reactions with eculizumab include headache (44%), nasopharyngitis (23%), back pain (19%), and nausea (16%).

Originator

Alexion (US)

Uses

Treatment of autoimmune disease such as rheumatoid arthritis, membranous nephritis, lupus nephritis, dermatomyositis, and autoimmune hemolytic anemias.

brand name

Soliris

General Description

Eculizumab (Soliris) is a monoclonal antibodythat binds to the terminal complement protein C5 inRBCs. This blocks the cleavage of C5 and halts the processof complement-mediated cell destruction of the RBCs.Eculizumab has been shown to be effective in treating PNHand in March 2007 was approved by the FDA for treatingPNH.

Clinical Use

Recombinant monoclonal antibody:
Paroxysmal nocturnal haemoglobinuria (PNH)
Atypical haemolytic uraemic syndrome (aHUS)
Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (MG)

Metabolism

Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolised by lysosomal enzymes to small peptides and amino acids.

Eculizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Eculizumab Suppliers

Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852 13308628970
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2866
Advantage
58
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4727
Advantage
58
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12335
Advantage
58
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3239
Advantage
55
Sichuan Wei Keqi Biological Technology Co., Ltd.
Tel
028-81700200 18116577057
Fax
028-81705658
Email
3003855609@qq.com
Country
China
ProdList
7887
Advantage
56
Taizhou KEDE Chemical Co., Ltd
Tel
0576-84613060 13093829633
Fax
0576-84613060
Email
sales@kedechemical.com
Country
China
ProdList
298
Advantage
60
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Fax
-
Email
xg01_gj@163.com
Country
China
ProdList
9484
Advantage
50
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
Fax
+86-21-52996696
Country
China
ProdList
4566
Advantage
55
Shanghai Hanjing Chemicals Co., Ltd.
Tel
021-54285032 13641685631
Fax
+86 (21) 5443 7651
Email
gerry.shu@hanjingchemicals.com
Country
China
ProdList
76
Advantage
55
More
Less

View Lastest Price from Eculizumab manufacturers

Career Henan Chemica Co
Product
Eculizumab 219685-50-4
Price
US $1.80/KG
Min. Order
1g
Purity
98%
Supply Ability
1KG/10KG/100KG
Release date
2020-11-02
Hangzhou Huarong Pharm Co., Ltd.
Product
Eculizumab 219685-50-4
Price
US $0.00-0.00/g
Min. Order
100mg
Purity
99%
Supply Ability
100KG
Release date
2021-09-15
Dideu Industries Group Limited
Product
Eculizumab 219685-50-4
Price
US $1.10/g
Min. Order
1g
Purity
99.9%
Supply Ability
100 Tons min
Release date
2021-08-17

219685-50-4, EculizumabRelated Search:


  • Alexion
  • Eculizumab
  • H5G1.1
  • H5G1.1Vhc H5G1.1vlc
  • Soliris
  • Unii-A3ulp0F556
  • ECULIZUMABUM
  • IMMunoglobulin,anti-(huMan coMpleMent C5 a-chain) (huMan-Mouse Monoclonal 5G1.1 heavy chain), disulfide withhuMan-Mouse Monoclonal 5G1.1 light chain, diMer (9CI)
  • Eculizumab, stock solution
  • ECULIZUMAB COMPLEMENT C5 219685-50-4
  • Eculizumab USP/EP/BP
  • Research Grade Eculizumab(DHB90002)
  • inhibit,C5a,C5b,haemolysis,membrane attack complex,humanized monoclonal antibody,Anti-Human C5, Humanized Antibody,Complement System,Eculizumab,complement C5,Inhibitor,MAC
  • Eculizumab (anti-Complement C5)
  • 219685-50-4